Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wet biological amniotic membrane is a biologic tissue-derived product developed by Guangzhou Ruitai Biotechnology and launched in China in December 2019. It is manufactured from fresh human amniotic membranes using a specialized process of rapid sampling, cutting, and irradiation sterilization designed to retain the tissue's natural biological activity. Clinically, it is primarily used in ophthalmology for the treatment of small corneal perforations (typically less than 3 mm in diameter) through a technique combining amniotic membrane plugging and transplantation. The membrane acts as a biological scaffold and reservoir for growth factors and extracellular matrix proteins that promote re-epithelialization and corneal healing while providing anti-inflammatory and anti-scarring properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on wet biological amniotic membrane.